文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

COVID-19与脓毒症综合征内皮病的生物标志物特征差异

Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes.
PubMed 文献 · Shock · 2022-01-01
一句话结论COVID-19患者内皮应激产物、补体激活和纤溶失调随病情严重度增加,且与脓毒性休克的内皮损伤模式不同。

该研究纳入COVID-19肺炎患者49例(按病情分为中度、重度、危重型),于住院48至72小时内采集血浆,检测内皮活化标志物sVCAM-1、VWF、ADAMTS-13活性、血栓调节蛋白、sTNFRI,内皮糖萼降解标志物硫酸乙酰肝素,补体激活标志物C5b9沉积及可溶性C5b9,NETs标志物循环dsDNA,以及纤溶参数α2-抗纤溶酶和PAI-1,并与健康对照45例比较;危重型COVID-19患者还与ICU内脓毒性休克14例、脓毒症7例、非感染性SIRS 7例比较。结果显示COVID-19患者除ADAMTS-13活性正常外所有标志物均较对照升高(P<0.001),sVCAM-1、VWF、sTNFRI和硫酸乙酰肝素升高与病情严重度相关(P<0.05);脓毒性休克患者VWF、血栓调节蛋白、sTNFRI和NETs显著高于危重型COVID-19,ADAMTS-13活性在脓毒性休克、脓毒症和非感染性SIRS中显著低于危重型COVID-19(P<0.001)。作者认为这些标志物有助于COVID-19病情分层,并可能为针对内皮病的治疗策略提供信息。

要点

  • COVID-19患者除ADAMTS-13活性正常外,所有检测的内皮损伤、补体激活和纤溶标志物均较健康对照升高(P<0.001)。
  • sVCAM-1、VWF、sTNFRI和硫酸乙酰肝素升高与COVID-19病情严重度相关(P<0.05)。
  • 脓毒性休克患者VWF、血栓调节蛋白、sTNFRI和NETs显著高于危重型COVID-19患者(P<0.001)。
  • ADAMTS-13活性在脓毒性休克、脓毒症和非感染性SIRS中显著低于危重型COVID-19(P<0.001)。
  • 危重型COVID-19的α2-抗纤溶酶活性高于非感染性SIRS(P<0.01)和脓毒性休克(P<0.001),PAI-1水平低于非感染性SIRS、脓毒症和脓毒性休克(P<0.01)。

适用人群与场景

  • COVID-19肺炎患者49例,按病情分为中度、重度、危重型(危及生命)。
  • 健康对照45例。
  • ICU内脓毒性休克患者14例、脓毒症患者7例、非感染性系统性炎症反应综合征患者7例。

研究设计与关键结果

  • 研究类型为比较性观察研究,纳入COVID-19肺炎患者49例、健康对照45例,并将危重型COVID-19与ICU内脓毒性休克14例、脓毒症7例、非感染性SIRS 7例比较。
  • 血浆样本于住院48至72小时内采集。
  • COVID-19患者所有分析标志物均较对照升高(P<0.001),但ADAMTS-13活性在两组均正常。
  • sVCAM-1、VWF、sTNFRI和硫酸乙酰肝素升高与COVID-19病情严重度相关(P<0.05)。
  • 脓毒性休克患者VWF、血栓调节蛋白、sTNFRI和NETs显著高于危重型COVID-19患者(P<0.001)。
  • ADAMTS-13活性在脓毒性休克、脓毒症和非感染性SIRS中显著低于危重型COVID-19(P<0.001)。
  • 危重型COVID-19的α2-抗纤溶酶活性高于非感染性SIRS(P<0.01)和脓毒性休克(P<0.001)。
  • COVID-19患者的PAI-1水平显著低于非感染性SIRS、脓毒症和脓毒性休克患者(P<0.01)。

证据类型、等级与局限

  • 证据类型:比较性观察研究(COVID-19不同临床阶段与脓毒症综合征及健康对照比较)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些生物标志物可帮助COVID-19病情严重度分层。
  • 作者认为这些生物标志物可能为针对内皮病进展的特定治疗策略提供信息。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Endotheliopathy is a key element in COVID-19 pathophysiology, contributing to both morbidity and mortality. Biomarkers distinguishing different COVID-19 phenotypes from sepsis syndrome remain poorly understood.

OBJECTIVE: To characterize circulating biomarkers of endothelial damage in different COVID-19 clinical disease stages compared with sepsis syndrome and normal volunteers.

METHODS: Patients with COVID-19 pneumonia (n = 49) were classified into moderate, severe, or critical (life-threatening) disease. Plasma samples were collected within 48 to 72 h of hospitalization to analyze endothelial activation markers, including soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1), von Willebrand Factor (VWF), A disintegrin-like and metalloprotease with thrombospondin type 1 motif no. 13 (ADAMTS-13) activity, thrombomodulin (TM), and soluble TNF receptor I (sTNFRI); heparan sulfate (HS) for endothelial glycocalyx degradation; C5b9 deposits on endothelial cells in culture and soluble C5b9 for complement activation; circulating dsDNA for neutrophil extracellular traps (NETs) presence, and α2-antiplasmin and PAI-1 as parameters of fibrinolysis. We compared the level of each biomarker in all three COVID-19 groups and healthy donors as controls (n = 45). Results in critically ill COVID-19 patients were compared with other intensive care unit (ICU) patients with septic shock (SS, n = 14), sepsis (S, n = 7), and noninfectious systemic inflammatory response syndrome (NI-SIRS, n = 7).

RESULTS: All analyzed biomarkers were increased in COVID-19 patients versus controls (P < 0.001), except for ADAMTS-13 activity that was normal in both groups. The increased expression of sVCAM-1, VWF, sTNFRI, and HS was related to COVID-19 disease severity (P < 0.05). Several differences in these parameters were found between ICU groups: SS patients showed significantly higher levels of VWF, TM, sTNFRI, and NETS compared with critical COVID-19 patients and ADAMTS-13 activity was significantly lover in SS, S, and NI-SIRS versus critical COVID-19 (P < 0.001). Furthermore, α2-antiplasmin activity was higher in critical COVID-19 versus NI-SIRS (P < 0.01) and SS (P < 0.001), whereas PAI-1 levels were significantly lower in COVID-19 patients compared with NI-SIRS, S, and SS patients (P < 0.01).

CONCLUSIONS: COVID-19 patients present with increased circulating endothelial stress products, complement activation, and fibrinolytic dysregulation, associated with disease severity. COVID-19 endotheliopathy differs from SS, in which endothelial damage is also a critical feature of pathobiology. These biomarkers could help to stratify the severity of COVID-19 disease and may also provide information to guide specific therapeutic strategies to mitigate endotheliopathy progression.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Fernández S, Moreno-Castaño AB, Palomo M, et al. Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022. PMID: 34172614. doi:10.1097/SHK.0000000000001823

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。